This inventor holds 2 USPTO granted patents. Top assignee: Wockhardt Limited. Active years: 2003-2006.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2003-2006
Title: Innovations of Dilip Ganesh Kulkarni
Introduction
Dilip Ganesh Kulkarni is a notable inventor based in Aurangabad, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of new drug formulations. With a total of 2 patents to his name, his work focuses on improving treatments for microbial infections.
Latest Patents
Kulkarni's latest patents include the invention of crystalline fluoroquinolone arginine salt forms. These inventions relate to new arginine salt forms of RS-(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, S-(-)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, and R-(+)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid. These patents also describe the processes for their preparation and pharmaceutical formulations that utilize these arginine salt forms as active ingredients for treating microbial infections.
Career Highlights
Dilip Kulkarni is currently employed at Wockhardt Limited, a prominent pharmaceutical company. His work at Wockhardt has allowed him to focus on innovative drug development and contribute to advancements in medical treatments.
Collaborations
Throughout his career, Kulkarni has collaborated with notable colleagues such as Noel J De Souza and Prasad Keshav Deshpande. These collaborations have fostered a productive environment for innovation and research in the pharmaceutical sector.
Conclusion
Dilip Ganesh Kulkarni's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to advancing medical science. His work continues to impact the treatment of microbial infections positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
